Oncternal Therapeutics (ONCT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ONCT Stock Forecast

Oncternal Therapeutics stock forecast is as follows: an average price target of $28.00 (represents a 2313.79% upside from ONCT’s last price of $1.16) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

ONCT Price Target

The average price target for Oncternal Therapeutics (ONCT) is $28.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $28.00. This represents a potential 2313.79% upside from ONCT's last price of $1.16.

ONCT Analyst Ratings

Buy

According to 6 Wall Street analysts, Oncternal Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ONCT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Oncternal Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 15, 2024	Raghuram Selvaraju	H.C. Wainwright	$28.00	$9.40	197.87%	2313.79%

Row per page

Go to

The latest Oncternal Therapeutics stock forecast, released on Apr 15, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $28.00, which represents a 197.87% increase from the stock price at the time of the forecast ($9.40), and a 2313.79% increase from ONCT last price ($1.16).

Oncternal Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$28.00
Last Closing Price	$1.16	$1.16	$1.16
Upside/Downside	-100.00%	-100.00%	2313.79%

In the current month, the average price target of Oncternal Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Oncternal Therapeutics's last price of $1.16. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Apr 15, 2024	H.C. Wainwright	Buy	Buy	Hold
Jan 29, 2024	Barclays	Buy	Buy	Hold
Dec 04, 2023	Brookline Capital	-	Buy	Upgrade
Sep 18, 2023	H.C. Wainwright	-	Buy	Upgrade
Mar 22, 2023	Oppenheimer	Outperform	Outperform	Hold
Dec 22, 2022	Cantor Fitzgerald	-	Overweight	Initialise
Feb 24, 2022	BTIG	-	Buy	Initialise

Row per page

Go to

Oncternal Therapeutics's last stock rating was published by H.C. Wainwright on Apr 15, 2024. The company gave ONCT a "Buy" rating, the same as its previous rate.

Oncternal Therapeutics Financial Forecast

Oncternal Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 12	Mar 11	Mar 10	Mar 09	Mar 08	Mar 07	Mar 06	Mar 05
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.14M	$2.13M	$883.00K	$748.00K	$1.59M	$585.00K	$1.83M	$9.29M	$56.58M	$3.63M	-	-	-	-
Avg Forecast	$200.00K	$200.00K	$200.00K	$200.00K	$275.00K	$275.00K	$212.50K	$183.33K	$128.00K	$125.00K	$170.83K	$166.67K	$331.50K	$325.00K	$459.00K	$525.00K	$1.06M	$1.30M	$1.09M	$1.11M	$587.50K	$623.00K	$1.63M	$13.56M	$54.26M	$4.30M	$3.73M	$1.97M	$1.19M	$677.59K
High Forecast	$200.00K	$200.00K	$200.00K	$200.00K	$275.00K	$275.00K	$212.75K	$183.50K	$195.76K	$125.00K	$170.83K	$166.67K	$331.50K	$325.00K	$459.00K	$525.00K	$1.06M	$1.30M	$1.09M	$1.11M	$587.50K	$623.00K	$1.95M	$16.27M	$65.11M	$5.16M	$4.47M	$2.36M	$1.43M	$813.11K
Low Forecast	$200.00K	$200.00K	$200.00K	$200.00K	$275.00K	$275.00K	$212.25K	$183.17K	$75.29K	$125.00K	$170.83K	$166.67K	$331.50K	$325.00K	$459.00K	$525.00K	$1.06M	$1.30M	$1.09M	$1.11M	$587.50K	$623.00K	$1.30M	$10.85M	$43.41M	$3.44M	$2.98M	$1.58M	$952.63K	$542.07K
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	7	9	9	10	20	12	17	8
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.98%	1.64%	0.81%	0.67%	2.70%	0.94%	1.13%	0.69%	1.04%	0.84%	-	-	-	-

Oncternal Therapeutics's average Quarter revenue forecast for Mar 22 based on 1 analysts is $525.00K, with a low forecast of $525.00K, and a high forecast of $525.00K. ONCT's average Quarter revenue forecast represents a -116.70% decrease compared to the company's last Quarter revenue of $-3.14M (Dec 21).

Oncternal Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 12	Mar 11	Mar 10	Mar 09	Mar 08	Mar 07	Mar 06	Mar 05
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	7	9	9	10	20	12	17	8
EBITDA	-	-	-	-	-	-	-	-	-	$-10.39M	$-9.54M	$-12.14M	$-11.91M	$-11.32M	$-11.79M	$-9.91M	$-8.07M	$-9.63M	$-7.68M	$-5.95M	$-2.56M	$-4.39M	$-10.87M	$-2.28M	$44.78M	$-11.04M	-	-	-	-
Avg Forecast	$-120.00K	$-120.00K	$-120.00K	$-120.00K	$-165.00K	$-165.00K	$-127.50K	$-110.00K	$-76.80K	$-75.00K	$-102.50K	$-100.00K	$-198.90K	$-195.00K	$-275.40K	$-9.91M	$-634.08K	$-778.80K	$-653.25K	$-4.76M	$-352.50K	$-5.57M	$-9.66M	$-3.32M	$42.94M	$-13.07M	$-12.64M	$-11.08M	$-9.80M	$-9.05M
High Forecast	$-120.00K	$-120.00K	$-120.00K	$-120.00K	$-165.00K	$-165.00K	$-127.35K	$-109.90K	$-45.18K	$-75.00K	$-102.50K	$-100.00K	$-198.90K	$-195.00K	$-275.40K	$-7.93M	$-634.08K	$-778.80K	$-653.25K	$-3.81M	$-352.50K	$-4.45M	$-7.73M	$-2.66M	$51.53M	$-10.46M	$-10.12M	$-8.87M	$-7.84M	$-7.24M
Low Forecast	$-120.00K	$-120.00K	$-120.00K	$-120.00K	$-165.00K	$-165.00K	$-127.65K	$-110.10K	$-117.46K	$-75.00K	$-102.50K	$-100.00K	$-198.90K	$-195.00K	$-275.40K	$-11.89M	$-634.08K	$-778.80K	$-653.25K	$-5.71M	$-352.50K	$-6.68M	$-11.59M	$-3.99M	$34.35M	$-15.68M	$-15.17M	$-13.30M	$-11.76M	$-10.86M
Surprise %	-	-	-	-	-	-	-	-	-	138.53%	93.12%	121.43%	59.90%	58.08%	42.83%	1.00%	12.73%	12.37%	11.76%	1.25%	7.25%	0.79%	1.13%	0.69%	1.04%	0.84%	-	-	-	-

9 analysts predict ONCT's average Quarter EBITDA for Mar 11 to be $-3.32M, with a high of $-2.66M and a low of $-3.99M. This is -107.42% lower than Oncternal Therapeutics's previous annual EBITDA (Mar 10) of $44.78M.

Oncternal Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 12	Mar 11	Mar 10	Mar 09	Mar 08	Mar 07	Mar 06	Mar 05
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	7	9	9	10	20	12	17	8
Net Income	-	-	-	-	-	-	-	-	-	$-9.86M	$-8.97M	$-11.48M	$-10.88M	$-10.72M	$-11.63M	$-9.89M	$-8.07M	$-9.63M	$-7.68M	$-5.95M	$-2.56M	$-4.39M	$-11.08M	$-2.60M	$44.34M	$-11.30M	-	-	-	-
Avg Forecast	$-5.71M	$-5.59M	$-6.13M	$-6.78M	$-10.27M	$-9.53M	$-8.98M	$-8.52M	$-9.13M	$-8.58M	$-9.59M	$-11.76M	$-12.56M	$-14.09M	$-13.54M	$-9.90M	$-14.56M	$-9.47M	$-8.14M	$-4.76M	$-10.66M	$-5.57M	$-9.85M	$-3.79M	$42.52M	$-13.38M	$-10.62M	$-9.67M	$-9.77M	$-8.96M
High Forecast	$-5.71M	$-5.59M	$-6.13M	$-6.78M	$-10.27M	$-9.53M	$-8.98M	$-8.52M	$-6.71M	$-8.58M	$-9.59M	$-11.76M	$-12.56M	$-14.09M	$-13.54M	$-7.92M	$-14.56M	$-9.47M	$-8.14M	$-3.81M	$-10.66M	$-4.45M	$-7.88M	$-3.03M	$51.03M	$-10.71M	$-8.50M	$-7.73M	$-7.81M	$-7.16M
Low Forecast	$-5.71M	$-5.59M	$-6.13M	$-6.78M	$-10.27M	$-9.53M	$-8.98M	$-8.52M	$-10.25M	$-8.58M	$-9.59M	$-11.76M	$-12.56M	$-14.09M	$-13.54M	$-11.88M	$-14.56M	$-9.47M	$-8.14M	$-5.71M	$-10.66M	$-6.68M	$-11.82M	$-4.54M	$34.02M	$-16.06M	$-12.74M	$-11.60M	$-11.72M	$-10.75M
Surprise %	-	-	-	-	-	-	-	-	-	1.15%	0.94%	0.98%	0.87%	0.76%	0.86%	1.00%	0.55%	1.02%	0.94%	1.25%	0.24%	0.79%	1.13%	0.69%	1.04%	0.84%	-	-	-	-

Oncternal Therapeutics's average Quarter net income forecast for Mar 11 is $-3.79M, with a range of $-4.54M to $-3.03M. ONCT's average Quarter net income forecast represents a -108.54% decrease compared to the company's last Quarter net income of $44.34M (Mar 10).

Oncternal Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 12	Mar 11	Mar 10	Mar 09	Mar 08	Mar 07	Mar 06	Mar 05
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	7	9	9	10	20	12	17	8
SG&A	-	-	-	-	-	-	-	-	-	$3.09M	$3.07M	$3.31M	$3.29M	$3.27M	$3.23M	$3.68M	$2.62M	$2.80M	$3.38M	$2.79M	$1.46M	$1.93M	$2.81M	$4.68M	$4.51M	$6.54M	-	-	-	-
Avg Forecast	$1.34M	$1.34M	$1.34M	$1.34M	$1.84M	$1.84M	$1.42M	$1.23M	$856.09K	$836.03K	$1.14M	$1.11M	$2.22M	$2.17M	$3.07M	$3.51M	$7.07M	$8.68M	$7.28M	$7.46M	$3.93M	$4.17M	$10.87M	$6.83M	$4.32M	$28.76M	$3.54M	$13.17M	$7.96M	$4.53M
High Forecast	$1.34M	$1.34M	$1.34M	$1.34M	$1.84M	$1.84M	$1.42M	$1.23M	$1.31M	$836.03K	$1.14M	$1.11M	$2.22M	$2.17M	$3.07M	$3.51M	$7.07M	$8.68M	$7.28M	$7.46M	$3.93M	$4.17M	$13.05M	$8.20M	$5.19M	$34.51M	$4.25M	$15.81M	$9.56M	$5.44M
Low Forecast	$1.34M	$1.34M	$1.34M	$1.34M	$1.84M	$1.84M	$1.42M	$1.23M	$503.58K	$836.03K	$1.14M	$1.11M	$2.22M	$2.17M	$3.07M	$3.51M	$7.07M	$8.68M	$7.28M	$7.46M	$3.93M	$4.17M	$8.70M	$5.47M	$3.46M	$23.01M	$2.83M	$10.54M	$6.37M	$3.63M
Surprise %	-	-	-	-	-	-	-	-	-	3.70%	2.69%	2.97%	1.48%	1.50%	1.05%	1.05%	0.37%	0.32%	0.46%	0.37%	0.37%	0.46%	0.26%	0.69%	1.04%	0.23%	-	-	-	-

Oncternal Therapeutics's average Quarter SG&A projection for Dec 23 is $856.09K, based on 3 Wall Street analysts, with a range of $503.58K to $1.31M. The forecast indicates a -72.33% fall compared to ONCT last annual SG&A of $3.09M (Sep 23).

Oncternal Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 12	Mar 11	Mar 10	Mar 09	Mar 08	Mar 07	Mar 06	Mar 05
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	7	9	9	10	20	12	17	8
EPS	-	-	-	-	-	-	-	-	-	$-0.17	$-0.15	$-0.20	$-0.19	$-0.20	$-0.23	$-0.20	$-0.16	$-0.19	$-0.16	$-0.12	$-0.09	$-0.22	$-12.60	$-3.50	$85.40	$-21.70	-	-	-	-
Avg Forecast	$-1.93	$-1.89	$-2.07	$-2.29	$-3.47	$-3.22	$-3.03	$-2.88	$-3.08	$-2.90	$-3.24	$-3.97	$-4.24	$-4.76	$-4.57	$-4.04	$-4.92	$-3.20	$-2.75	$-2.00	$-3.60	$-6.00	$-1.44	$-1.93	$11.24	$-4.50	$-2.50	$-3.38	$-3.10	$-3.60
High Forecast	$-1.93	$-1.89	$-2.07	$-2.29	$-3.47	$-3.22	$-3.03	$-2.88	$-2.27	$-2.90	$-3.24	$-3.97	$-4.24	$-4.76	$-4.57	$-4.04	$-4.92	$-3.20	$-2.75	$-2.00	$-3.60	$-6.00	$-1.15	$-1.54	$13.49	$-3.60	$-2.00	$-2.70	$-2.48	$-2.88
Low Forecast	$-1.93	$-1.89	$-2.07	$-2.29	$-3.47	$-3.22	$-3.03	$-2.88	$-3.46	$-2.90	$-3.24	$-3.97	$-4.24	$-4.76	$-4.57	$-4.04	$-4.92	$-3.20	$-2.75	$-2.00	$-3.60	$-6.00	$-1.73	$-2.31	$8.99	$-5.40	$-3.00	$-4.06	$-3.72	$-4.32
Surprise %	-	-	-	-	-	-	-	-	-	0.06%	0.05%	0.05%	0.04%	0.04%	0.05%	0.05%	0.03%	0.06%	0.06%	0.06%	0.02%	0.04%	8.75%	1.81%	7.60%	4.82%	-	-	-	-

According to 9 Wall Street analysts, Oncternal Therapeutics's projected average Quarter EPS for Mar 11 is $-1.93, with a low estimate of $-2.31 and a high estimate of $-1.54. This represents a -102.26% decrease compared to ONCT previous annual EPS of $85.40 (Mar 10).

Oncternal Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ADTX	Aditxt	$0.32	$160.00	49900.00%	-
ONCT	Oncternal Therapeutics	$1.16	$28.00	2313.79%	Buy
PASG	Passage Bio	$0.54	$6.00	1011.11%	Buy
CTMX	CytomX Therapeutics	$0.87	$5.73	558.62%	Buy
TIL	Instil Bio	$24.76	$78.25	216.03%	Hold
ADVM	Adverum Bio	$5.75	$15.00	160.87%	Buy
NUVB	Nuvation Bio	$2.70	$6.75	150.00%	Buy
ASMB	Assembly Biosciences	$14.72	$35.50	141.17%	Buy
ABSI	Absci	$2.55	$6.00	135.29%	Buy
KZR	Kezar Life Sciences	$7.62	$17.50	129.66%	Buy
MNPR	Monopar Therapeutics	$19.71	$29.50	49.67%	Buy

ONCT Forecast FAQ

Is Oncternal Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Oncternal Therapeutics (ONCT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of ONCT's total ratings.

What is ONCT's price target?

Oncternal Therapeutics (ONCT) average price target is $28 with a range of $28 to $28, implying a 2313.79% from its last price of $1.16. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Oncternal Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ONCT stock, the company can go up by 2313.79% (from the last price of $1.16 to the average price target of $28), up by 2313.79% based on the highest stock price target, and up by 2313.79% based on the lowest stock price target.

Can Oncternal Therapeutics stock reach $2?

ONCT's average twelve months analyst stock price target of $28 supports the claim that Oncternal Therapeutics can reach $2 in the near future.

What are Oncternal Therapeutics's analysts' financial forecasts?

Oncternal Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $945.83K (high $946.25K, low $945.42K), average EBITDA is $-567K (high $-567K, low $-568K), average net income is $-37.298M (high $-37.298M, low $-37.298M), average SG&A $6.33M (high $6.33M, low $6.32M), and average EPS is $-12.601 (high $-12.601, low $-12.601). ONCT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $800K (high $800K, low $800K), average EBITDA is $-480K (high $-480K, low $-480K), average net income is $-24.213M (high $-24.213M, low $-24.213M), average SG&A $5.35M (high $5.35M, low $5.35M), and average EPS is $-8.18 (high $-8.18, low $-8.18).

Did the ONCT's actual financial results beat the analysts' financial forecasts?

Based on Oncternal Therapeutics's last annual report (Dec 2021), the company's revenue was $4.32M, which missed the average analysts forecast of $4.56M by -5.34%. Apple's EBITDA was $-31.366M, beating the average prediction of $-6.825M by 359.61%. The company's net income was $-31.3M, missing the average estimation of $-36.934M by -15.25%. Apple's SG&A was $11.6M, missing the average forecast of $30.49M by -61.97%. Lastly, the company's EPS was $-0.63, missing the average prediction of $-12.87 by -95.10%. In terms of the last quarterly report (Dec 2021), Oncternal Therapeutics's revenue was $-3.144M, missing the average analysts' forecast of $1.06M by -397.50%. The company's EBITDA was $-8.073M, beating the average prediction of $-634K by 1173.18%. Oncternal Therapeutics's net income was $-8.066M, missing the average estimation of $-14.563M by -44.61%. The company's SG&A was $2.62M, missing the average forecast of $7.07M by -62.96%. Lastly, the company's EPS was $-0.16, missing the average prediction of $-4.92 by -96.75%